ESC 365 - Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

ESC Premium Access

Comparative safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Session: Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

Topic: Oral Anticoagulation

Speaker: Professor H. Bonnemeier (Luebeck, DE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Hendrik Bonnemeier

Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)

6 presentations

0 follower

9 more presentations in this session

Performance of the HAS-BLED, ATRIA, and PRECISE-DAPT Bleeding Risk Scores in Atrial Fibrillation Patients Using Antiplatelet Agents or Oral Anticoagulants

Speaker: Mr J. Choi (Busan, KR)

Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease

Speaker: Doctor J. Strange (Copenhagen, DK)

Comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in the elderly asian patients with atrial fibrillation

Speaker: Doctor T. Chao (Taipei, TW)

Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis

Speaker: Mrs A. Kang (Princeton, US)

Risk prediction of atrial fibrillation in the community combining biomarkers and genetics

Speaker: Doctor C. Boerschel (Hamburg, DE)

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 6

Speakers: Professor H. Bonnemeier, Mr J. Choi, Doctor J. Strange, Doctor T. Chao, Mrs A. Kang...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources